Fig. 2.

BAG3 transgenic mice show relieved Ang II-associated vascular endothelial damage and post-injury remodeling

(A) BAG3-WT and BAG3-TG mice were administered Ang II (1.5 mg/kg/day) or not by the subcutaneous route at 0.5 μl/h for 14 days. Euthanasia was carried out by cervical dislocation after the 14-day treatment. B) H&E, (C) Masson and (D) DHE staining was carried out for assessing vascular thickening, fibrosis and oxidative stress injury, respectively. Scale bar, 100 μm. Data are mean ± SD (n = 6; ***P < 0.001, two-way ANOVA with post hoc Bonferroni test). (E) Vascular tissue samples from BAG3-WT and BAG3-TG mice infused without or with Ang II for 14 days were examined by immunoblot for BAG3, PARP1 and cleaved caspase-3. Data are mean ± SD (n = 6; **P < 0.01, two-way ANOVA with post hoc Bonferroni test). (F) Col-1 and a-SMA protein amounts assessed by immunoblot. Data are mean ± SD (n = 6; **P < 0.01, two-way ANOVA with post hoc Bonferroni test). (G) 3-Nitrotyrosine, OGG1 and SOD1 protein amounts assessed by immunoblot. Data are mean ± SD (n = 6; **P < 0.01, two-way ANOVA with post hoc Bonferroni test).